A pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Yowza! Another super-volatile lifetime share price chart. Don't look directly at it unless you want to get vertigo. And yes, that was a new six-year low today. Pozen's executives have had long and remunerative careers developing uninspiring combination pharmaceuticals that nobody really seems to want. Treximet, yawn. Adding an NSAID to a triptan has been good for 4M per quarter. And Vimovo hasn't yet cracked a million in quarterly royalties. And now there's PA32540 about to make enteric-coated aspirin even safer for sensitive stomachs. Has the market finally tired of this eleven year unprofitable story? Or will management's expertise in selling themselves resuscitate the stock from another depression? My years watching these stocks indicate the latter.